

第 95 卷 索 引

I		empiric therapy	301
(1 → 3)-β-D-glucan		encephalitis	407
		enzyme-linked immunosorbent assay	329
A		F	
abdominal aortic aneurysm	27	full genome	293
<i>Acinetobacter</i>	301	G	
African tick-bite fever	133	gastroenteritis	360
antibody test	353	gastrointestinal infection	117
antigen test	307	genetic testing	117
antimicrobial resistance	122	H	
antimicrobial stewardship	122	<i>Helicobacter cinaedi</i>	27
artemether-lumefantrine	339	hemodialysis	319
B		household infection	391
bacteremia	301, 314, 324	human metapneumovirus	396
<i>Balamuthia mandrillaris</i>	407	I	
baloxavir marboxil	1	immunoglobulin	372
β-lactamase-negative ampicillin-resistant	137	infection control	129, 307
C		influenza	1, 9
cardiomyopathy	372	intrinsic resistance	17
catch-up immunization for adults	353	invasive <i>Haemophilus influenzae</i> disease	137
cephalosporin	122	isolation in facilities	391
cerebral infarction	335	K	
Chiba prefecture	37	Kawasaki disease	377
chromogenic assay	329	Kikuchi-Fujimoto disease	401
computed tomography	21	<i>Klebsiella pneumoniae</i>	324
consolidation	21	L	
COVID-19	21, 32, 37, 129, 147, 293, 307, 377, 381, 391, 396, 401	lung cancer	314
cryptococcus meningoencephalitis	335	M	
D		malaria	339
dentist	122	matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS)	17, 27
disseminated gonococcal infection	348, 367	medical evacuation	141
E		MMRV	353
eculizumab	348, 367		
effective reproduction number	37		
elderly patients	1		

monoresistance	343	re-positive	32
mother to child transmission	129	real time RT-PCR	307
multidrug resistance	141	recurrence	339
multilocus sequence typing	335	remdesivir	147
multiplex-PCR	396	respiratory failure	147
multisystem inflammatory syndrome in children (MIS-C)	377	<i>Rickettsia africae</i>	133
N		rotavirus gastroenteritis	360
necrotizing fasciitis	324	rotavirus vaccine effectiveness	360
<i>Neisseria gonorrhoeae</i>	367	rotavirus vaccine vaccination rate	360
non-O1	314	RT-PCR	32
non-O139 <i>Vibrio cholerae</i>	314	S	
P		SARS-CoV-2	293, 307, 391
patients at high risk of influenza complication	1	sensitivity and specificity	9
pharmacokinetics	319	subacute necrotizing lymphadenitis	401
<i>pncA</i> gene	343	T	
point of care testing	9	tenofovir	319
pretravel consultation	353	time course	9
prophylaxis	122	toxic shock syndrome	372
pulmonary nocardiosis	17	tozinameran	381
pyrazinamide	343	transmission	293
Q		travel clinic	385
questionnaire	117	travel medicine	133, 385
R		turbidimetric assay	329
rapid influenza diagnostic test	9	type f	137
		V	
		vaccine	381